Key Takeaways
- President Trump facilitated a significant Middle East peace deal involving Israel and Hamas, leading to hostage releases and credit for his dealmaking skills.
- Dr. Patrick Soon-Shiong detailed the LA Times' decision not to endorse Kamala Harris and his efforts to democratize media ownership and content.
- Soon-Shiong highlighted his frustrations with the FDA's regulatory process hindering the widespread adoption of his cancer treatment, which stimulates natural killer cells.
- The episode explored the complexities of the Israel-Hamas conflict, including prisoner exchanges, propaganda, and shifts in US public support for Israel.
Deep Dive
- President Trump reportedly informed families of Israeli hostages about their loved ones' release as part of a significant Middle East peace deal involving Israel and Hamas.
- This deal is framed as a defining moment in Trump's legacy, with even media critics acknowledging his dealmaking skills, often compared to real estate negotiations.
- Efforts by Steve Witkoff and Jared Kushner were highlighted in securing international backing for the agreement.
- The release of hostages, including those from a music festival attack, brought joy to Israelis, while significant Palestinian casualties in Gaza were acknowledged.
- Israel agreed to release approximately 3,000 Palestinians in exchange for 48 hostages, with only 20 confirmed alive.
- The discussion noted a perceived disparity in the value placed on life by Israel and Hamas, with criticism of media coverage for alleged propaganda.
- Hamas is described as effective at propaganda, exploiting narratives of oppression to erode public support for Israel, particularly among younger US demographics.
- The October 7th attack was identified as the second-largest mass casualty terror attack of the era, following 9/11.
- Israeli actions are noted to have weakened Iran and its associated groups like Hezbollah and the Houthis, improving regional stability.
- Speculation arose about President Trump potentially receiving a Nobel Peace Prize for his Middle East deal, prompting mixed reactions from media outlets like NPR and CNN.
- Buck Sexton defended Trump's character, asserting he cares about people and does not want to see suffering, while criticizing the credibility of past Nobel Peace Prize recipients.
- The host and guest observed a lack of public statements from prominent Democrats regarding the Middle East deal, contrasting with critical media coverage.
- Dr. Patrick Soon-Shiong, CEO of Los Angeles Times Media Group, explained his decision to stop the paper from endorsing Kamala Harris, stating he didn't believe she would be a competent president.
- This decision led to significant backlash at the LA Times, including the resignation of most of the editorial board.
- Soon-Shiong is launching the Graphene platform to democratize media ownership, allowing investments as low as $500, aiming to distinguish factual news from opinion.
- Dr. Soon-Shiong detailed his frustration with the FDA and regulatory bodies, describing them as bureaucratic and resistant to scientific advancement.
- His research focuses on activating natural killer cells with IL-15 to attack various cancers, with one treatment approved for bladder cancer after 10 years, leading to decade-long remission for patients.
- The FDA refused to review data for other cancer types, demanding separate randomized trials for each despite the treatment's established mechanism.
- Dr. Soon-Shiong recounts developing a COVID-19 'vaccine' (BioShield) designed to stimulate T-cells for long-lasting memory and clear the virus, unlike existing vaccines targeting changing spike proteins.
- He proposed to Operation Warp Speed that all vaccines be tested for viral clearance, noting BioShield was the only one that succeeded in this regard.
- During the Biden administration, his application for a booster was refused by the FDA, with officials reportedly unable to explain the refusal or their understanding of T cells.
- The conversation addressed increasing rates of cancer, particularly aggressive forms in young people, including anecdotal cases of colon and pancreatic cancer.
- Dr. Soon-Shiong's treatment involves a subcutaneous IL-15 injection that proliferates natural killer (NK) and T cells, showing success in metastatic pancreatic, Merkel cell, and bladder cancers.
- He critiques current cancer protocols, arguing chemotherapy and radiation eliminate crucial NK and T cells, advocating for his immune-boosting treatment to be initiated first to improve long-term survival.
- Dr. Soon-Shiong described frustrating interactions with FDA reviewers over his bladder cancer treatment, contrasting their resistance to his proposed trial with the expedited approval of chemotherapy with known side effects.
- His past successes include inventing Abraxane, a breast cancer drug generating a billion dollars, and a safe heparin alternative that prevented deaths from contamination.
- He chose to sell his companies, driven by scientific impact over personal wealth, even offering to donate a COVID-19 vaccine, highlighting regulatory hurdles as a major impediment.
- Dr. Soon-Shiong expressed hope that President Trump could help implement his cancer breakthrough, preventing and curing cancer, potentially cementing Trump's legacy akin to Middle East peace.
- He highlighted the rise of aggressive cancers in young people, suggesting a link to COVID-19 or vaccines affecting the p53 gene, which is crucial for cancer prevention.
- Soon-Shiong believes Trump could make his already FDA-approved bladder cancer drug more accessible for other tumor types, citing the difficulty and cost of individual randomized trials.